Allogene Therapeutics, Inc. (ALLO) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

43NeutralDD: Jul 22, 2026Analyst: 53

paidPrice at analysis date

USD 1.95 (22/07/2026)

domainMkt cap

$674M

pie_chartShares

345.15M

candlestick_chart52W

$0.98-$4.46

trending_downShort interest

18.36%

MEDIUMNASDAQHealth Care152 employeesFounded 2018

Verdict: Moderately Attractive — Pipeline optionality with binary risk anchored to cash floor

Clinical-stage allogeneic CAR-T platform trading at $1.95 with $266.9M cash + $185.8M net cash ($0.54/sh). Cema-cel ALPHA3 pivotal Phase 2 in 1L LBCL delivered positive MRD interim Apr 2026 (58.3% vs 16.7% observation). Primary EFS mid-2028 = the value inflection. ALLO-329 autoimmune (3 FDA Fast Tracks) opens large second TAM. Base rNPV FV $2.75 = +41% upside vs current; downside to cash floor −72%. Analyst PT $8.49 (median, 13 analysts) prices success. High short interest 18.4% + CEO transition adds noise. Speculative — position size for binary risk.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-22

Allogene Therapeutics, Inc. (ALLO)

Allogeneic CAR-T · NASDAQ · South San Francisco, CA

"Pipeline optionality + cash floor — but binary trial risk and heavy dilution"

ALPHA3 MRD positive Apr 26 3 FDA Fast Tracks Cash to Q1 2029 Short interest 18.4% Dilution +9.9% YoY

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — Risk-adjusted NPV (rNPV) by asset, minus burn and dilution reserve

Fair value base case

USD 2.75

Range: USD 0.85-USD 5.50

Price at analysis date: USD 1.95 (22/07/2026)

Base upside/downside: +41%

rNPV probability-weighted sum-of-parts. Weighted average scenario FV = 0.20 × 5.25 + 0.50 × 3.00 + 0.30 × 1.05 = $2.87 — reconciles within 5% of base rNPV $2.69, confirming FV base ~$2.75. Sensitivity: cema-cel PoS drives 65% of FV; ±5 pp on that assumption moves FV by ±$0.36. Cross-check via peer MktCap/Cash suggests ALLO fairly priced. ⚠️ Not investment advice.

Component	Assumption	USD/share
Cema-cel (ALPHA3, 1L LBCL)	30% PoS × $2.5B risk-adj NPV (peak $500M sales, 60% margin, 10x EV/EBITDA, 12% WACC to 2029) / 345.15M sh	+2.17
ALLO-316 (RCC / solid tumors)	15% PoS × $500M NPV (Phase 1 durable responses, RCC + expansion CD70+ tumors) / 345.15M sh	+0.22
ALLO-329 (autoimmune basket)	15% PoS × $2.0B NPV (3 FDA Fast Tracks — lupus, myositis, scleroderma; TAM >200K US SLE alone) / 345.15M sh	+0.87
Dagger platform / preclinical optionality	10% × $500M NPV (Dagger anti-rejection tech, partnering + follow-on programs) / 345.15M sh	+0.15
Cash (gross)	$266.9M cash & equivalents / 345.15M sh (Q1 2026 post-Apr $200M PIPE)	+0.77
Debt (net out)	−$81.05M total debt / 345.15M sh (convertible notes + Servier obligations)	−0.23
Future cash burn to Q1 2029	−$330M operating burn 2026E-2028E (~$165M/yr × 2 yr) / 345.15M sh	−0.96
Dilution reserve	~15% add'l share issuance 2027-2028 at $2 avg = ~52M new sh, dilutive impact modeled	−0.30
FV base case	Sum: 2.17 + 0.22 + 0.87 + 0.15 + 0.77 − 0.23 − 0.96 − 0.30	≈ $2.69

Bull

$5.00–$5.50

Probability: 20%

Interim EFS mid-2027 positive, cema-cel filed 2028, ALLO-329 shows lupus PoC data, partnership/M&A speculation ramps. Multiple re-rates on de-risked assets.

Base

$2.50–$3.50

Probability: 50%

ALPHA3 progresses to primary EFS mid-2028; ALLO-329 modest early data; ~15% additional dilution required. Fair value crystallizes around net cash + risk-adjusted pipeline.

Bear

$0.85–$1.20

Probability: 30%

Primary EFS misses or interim signals softening; ALLO-329 disappoints; forced dilutive raise 2027-2028 at <$1. Stock retests $0.98 52W low or below.

Methodology: rNPV probability-weighted sum-of-parts. Weighted average scenario FV = 0.20 × 5.25 + 0.50 × 3.00 + 0.30 × 1.05 = $2.87 — reconciles within 5% of base rNPV $2.69, confirming FV base ~$2.75. Sensitivity: cema-cel PoS drives 65% of FV; ±5 pp on that assumption moves FV by ±$0.36. Cross-check via peer MktCap/Cash suggests ALLO fairly priced. ⚠️ Not investment advice. Not investment advice.

warning

🚨 Pre-revenue with binary trial risk + persistent dilution — position sizing critical

Zero commercial revenue TTM. Net loss $173.8M; operating cash burn guided ~$165M in 2026 (raised from $150M). Cash runway extended to Q1 2029 after $200M April 2026 PIPE offering — but at cost of +9.9% YoY dilution. Short interest at 18.36% of shares outstanding (23.42% of float, 6.35 days to cover) reflects deep skepticism. Primary EFS readout of ALPHA3 not until mid-2028 = 2-year event risk with likely another dilutive raise in between. Preliminary proxy authorization to double authorized shares filed.

⚠️ Methodology note: Clinical-stage biotech pre-approval — traditional multiples (P/E, EV/EBITDA, EV/Sales) are not meaningful. Fair value built as risk-adjusted NPV (rNPV) of each pipeline asset, using industry-standard probability of technical success (PoS) x peak-sales-derived NPV, added to net cash floor and net of estimated future burn + dilution reserve. Peer comparables use market-cap-to-cash and stage-adjusted enterprise value as proxies. rNPV assumptions are inherently subjective — analyst consensus PT $8.49 implies significantly higher PoS estimates than base case here.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

18.36%

63.39M shares short on 345.15M outstanding (23.42% of float); DTC 6.35 days. Rising from 48.04M previous month. Very high — reflects skepticism on primary EFS readout timing + dilution risk. Squeeze setup on strong catalyst.

🔴 Share Dilution (1Y)

+9.93%

Q1 26 alone +6.31% QoQ. Apr 2026 PIPE offering raised $200M gross at ~$2.05 = ~98M new shares. Preliminary proxy filed to double authorized share count. Further dilution near-certain 2027-2028.

🔴 Buyback

Zero buyback authorization. Priority: preserve cash for pipeline development. Cash preservation vs share retirement is the appropriate use given pre-revenue stage and 2-year event horizon.

Short Interest — context

ALLO — 18.36% (SOS)

18.36%

SI as % of float

23.42%

Insider transactions: routine Form 144 filings from officers (tax-related RSU vesting). No material open-market sales >$500K threshold. Beneski (SVP) sold 5,488 sh on 2025-03-18 (~$10K). New CEO Zachary Roberts received option to purchase 476,190 sh + 134,530 RSUs upon assuming CEO role Jul 1 2026 — standard package. Institutional ownership 42.42%. No active securities class action against ALLO directly; indirect exposure to Cellectis-Factor Bioscience TALEN patent dispute (Servier arbitration ruled favorably for Servier/Allogene position).

$Financial analysis — FY 2023–2027E

Revenue TTM

$0M

Pre-revenue

Cash (Q1 2026)

$266.9M

Runway to Q1 2029

Net loss TTM

−$173.8M

EPS −$0.77

FY26 opex guide

~$165M

Raised from $150M

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2027E
Revenue ($M)	0.0	0.0	0.0	0.0	0.0 (no launch)
Operating loss ($M)	−240	−210	−200	−225	−220 (est.)
Net loss ($M)	−225	−200	−190	−215	−210 (est.)
Operating cash expense ($M)	−180	−160	−150	−165	−155 (est.)
Cash EoP ($M)	530	380	230	~360 post-PIPE	~195 pre-raise
Shares outstanding (M)	170	195	315	~380 (est.)	~430 (est.)

Note: Q1 2026 cash EoP $266.9M includes $200M PIPE proceeds from April 2026 raise. FY26 opex guidance raised from $150M to $165M for CEO transition + ALLO-329 acceleration. FY27 shares outstanding assume additional dilutive raise at low prices.

Quarterly dynamics — last 5 quarters
Metric	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Revenue ($M)	0.0	0.0	0.0	0.0	0.0
Operating expenses ($M)	50	48	52	50	56
Net loss ($M)	−45	−46	−52	−47	−43
EPS ($)	−0.24	−0.24	−0.27	−0.24	−0.18
Cash EoP ($M)	380	335	285	230	267

Financial position and sustainability

Cash floor / market cap

40%

Cash runway (management guide)

Q1 2029

ALPHA3 primary EFS timeline

Mid-2028

Short interest / float

23.42%

account_tree

Business model — Allogeneic (off-the-shelf) CAR-T platform for oncology + autoimmune

First-mover in scalable, off-the-shelf CAR-T pivotal trials

Allogene develops allogeneic (donor-derived, off-the-shelf) CAR-T cell therapies. Unlike autologous CAR-T (Kymriah, Yescarta, Breyanzi) where each patient's cells are engineered individually — expensive, weeks to manufacture — allogeneic CAR-T is manufactured in bulk from healthy donors and stored frozen for on-demand use. Key innovation: Dagger® anti-rejection technology reduces host-vs-graft immune rejection. Lead asset cema-cel (formerly ALLO-501) in pivotal ALPHA3 trial for 1L LBCL consolidation. Pipeline expansion into solid tumors (ALLO-316, CD70+ RCC) and autoimmune (ALLO-329, CD19/CD70 dual for lupus/myositis/scleroderma). Backed by Servier license (from Cellectis heritage).

Cema-cel — 1L LBCL (ALPHA3) Peak $500M+ · Filed 2028E 🟢 Pivotal Ph2, interim MRD+ Allogeneic CD19 CAR-T as 1L consolidation for high-risk LBCL. April 2026 interim: 58.3% MRD clearance vs 16.7% obs. 33% of infusions at community centers. Primary EFS mid-2028. ALLO-316 — RCC / solid tumors Peak $300M+ · Ph2 initiation 2027E 🟡 Phase 1 durable data Allogeneic CD70 CAR-T. TRAVERSE Phase 1 published JCO Jul 2026: 31% cORR in advanced RCC with high CD70; responses 8-18+ mo. Expansion into CD70+ hematologic + other solid tumors. ALLO-329 — Autoimmune basket Peak $2B+ · Ph2 initiation 2027E 🟢 3 FDA Fast Tracks Dual CD19/CD70 CAR-T with Dagger. RESOLUTION Ph1 basket enrolling (lupus, myositis, scleroderma). Initial data June 2026 (positive translational signals). Year-end 2026 update planned.

2026 catalyst pack: (1) ALPHA3 initial EFS interim mid-2027, (2) ALLO-329 first data update Q4 2026, (3) ALLO-316 solid-tumor expansion protocol amendments. Q2 2026 earnings Aug 12 (after market close). CEO transition to Zachary Roberts Jul 1 (previously Chief Medical Officer, drove clinical development since 2023 — continuity risk manageable).

gavel

Legal, regulatory and risk analysis

ALPHA3 primary EFS binary risk (mid-2028)

Critical

Existential. Positive primary event-free survival = commercial de-risking, potential $5+ stock. Miss = stock retests $0.85-$1.00 cash floor. Interim MRD data positive but MRD-to-EFS correlation not fully validated in allogeneic CAR-T. Interim EFS look mid-2027 provides earlier read.

Cash runway to Q1 2029 + Dagger tech optionality

Positive

$266.9M cash, $185.8M net cash, extended runway to Q1 2029 after $200M April PIPE. Adequate to reach interim EFS (mid-2027) and one dilutive raise beyond. Dagger anti-rejection platform is a differentiated moat vs peer allogeneic programs.

Dilution — $200M PIPE Apr 2026 + more coming

High

+9.93% YoY dilution already. Preliminary proxy filed to double authorized shares (potential warning). Almost-certain additional raise 2027-2028 to bridge to potential 2029 approval + launch. Historical experience: pre-revenue biotechs dilute 15-30% per raise at low prices.

ALLO-329 autoimmune — massive optionality

Positive

3 FDA Fast Tracks (lupus, myositis, scleroderma). Autoimmune CAR-T is a hot space with TAM >200K US SLE alone. Dagger enables reduced lymphodepletion — critical differentiator for rheumatology adoption vs oncology-heavy autologous protocols.

Short interest 18.4% + high squeeze potential

Moderate

63M shares short = deep skepticism but also asymmetric upside on positive catalysts. Interim EFS mid-2027 or ALLO-329 lupus response data could trigger squeeze. Also amplifies downside on any negative headline. Beta 0.46 low but SI-driven volatility can decouple from market moves.

CEO succession Jul 1 2026 (Chang → Roberts)

Moderate

Founder-CEO David Chang stepping down to Board. Zachary Roberts (former CMO, drove clinical dev since 2023) elevated. Continuity risk manageable given Roberts led key ALPHA3 protocol design. But leadership transition around pivotal readouts adds noise; potential for revised strategic direction / partnership announcement.

Competitive: autologous CAR-T incumbents + allogeneic peers

Moderate

Autologous CAR-T (Yescarta, Kymriah, Breyanzi) are FDA-approved and Medicare-covered in 2L+ LBCL. Allogeneic must prove non-inferiority + accessibility premium. CRSP (CTX112), Caribou, Precision, 2seventy bio are allogeneic peers. Cema-cel unique in 1L consolidation targeting — differentiated positioning.

Cellectis-Factor Bioscience patent dispute (indirect)

Low

Cellectis (Allogene's TALEN gene-editing licensor) faces Factor Bioscience litigation. Allogene not directly named. Recent Servier arbitration ruled favorably. Manageable indirect risk; not material to near-term valuation.

article

SWOT analysis

Strengths

+Pivotal Phase 2 (ALPHA3) with positive interim MRD data Apr 2026
+First allogeneic CAR-T positioned for 1L LBCL consolidation (community-friendly)
+Cash runway extended to Q1 2029 (post-Apr $200M PIPE)
+Dagger anti-rejection platform = differentiated tech moat
+3 FDA Fast Track designations on ALLO-329 (lupus, myositis, scleroderma)

Weaknesses

−Pre-revenue: zero commercial sales, $173M annual net loss
−Heavy dilution: +9.93% YoY, PIPE at low prices, proxy to double share count
−Primary EFS readout not until mid-2028 = 2-year event risk
−CEO transition Jul 2026 (Chang → Roberts) adds narrative uncertainty
−Small institutional ownership 42% vs biotech peer 60-70% average

Opportunities

→Interim EFS mid-2027 = de-risking event 12 months before primary
→ALLO-329 in autoimmune = second growth engine with $2B+ TAM
→Short squeeze potential 18.4% SI on positive catalyst
→M&A / partnership speculation (allogeneic scarcity in space)
→Multiple re-rating toward CRSP-like MktCap/Cash if trials succeed

Threats

!ALPHA3 EFS miss = stock retests $0.98 52W low or below
!Autologous CAR-T incumbents entrench in 1L (Yescarta, Breyanzi)
!Additional dilutive raise 2027-2028 at <$2/sh = destructive to per-share value
!Broader biotech risk-off could compress multi-year clinical-stage valuations

article

Summary by assessment area

🟡 Financial risk — Moderate

$266.9M cash, runway to Q1 2029
$81M debt vs cash = manageable
Dilution near-certain 2027-2028
$165M annual burn

🔴 Business risk — High

Pre-revenue: zero commercial sales
Primary EFS binary mid-2028
Autologous CAR-T entrenched competition
CEO transition adds execution risk

🟡 Risk/reward — Neutral-Positive

FV base $2.75 vs $1.95 → +41% upside
Bull $5-5.50 (analyst PT range)
Bear $0.85-1.20 (near cash floor)
Position size for binary outcome

2026-08-12 earnings

Q2 2026 Earnings Release

short-term Impact: High Direction: Binary

First earnings under CEO Roberts. Investors will watch: cash burn trajectory, ALPHA3 enrollment progress, ALLO-329 update timing confirmation, any reaffirm/change of FY26 opex guide $165M and runway to Q1 2029.

2026-12-15 product

ALLO-329 Phase 1 RESOLUTION year-end data update

medium-term Impact: High Direction: Bullish

Follow-up data on ALLO-329 dose escalation in autoimmune basket. Positive clinical outcomes in lupus/myositis/scleroderma = major re-rating catalyst on 2nd platform validation. Cabaletta (CABA), Bristol (breyanzi in autoimmune) comparators.

2027-06-30 product

ALPHA3 interim EFS analysis (mid-2027)

long-term Impact: High Direction: Binary

First interim event-free survival readout. Provides early de-risking of the primary endpoint (mid-2028). Positive trend = stock could re-rate 100%+. Weak signal = binary event compression, potential −40% move.

2028-06-30 product

ALPHA3 primary EFS readout (mid-2028) — value inflection

long-term Impact: High Direction: Binary

The determining event for cema-cel commercial thesis. Positive EFS = BLA filing late 2028, potential launch 2029. Miss = cema-cel program collapse, stock likely below cash floor. Options market will implode volatility ahead of readout.

2027-03-31 product

ALLO-316 Phase 2 initiation in RCC / expansion cohorts

medium-term Impact: Medium Direction: Bullish

Following JCO publication of Phase 1 data Jul 2026 (31% cORR, durable responses), advancement to Phase 2 in solid tumors validates CD70 platform. Expansion into CD70+ hematologic malignancies possible.

2027-09-30 capital_markets

Expected follow-on equity raise 2027 (bridge to primary EFS)

long-term Impact: High Direction: Bearish

Cash runway to Q1 2029 implies raise in 2H27 to comfortably fund through mid-2028 primary EFS + potential BLA filing. Timing likely post-interim EFS look to raise at higher prices — but if interim weak, dilution painful.

2026-12-31 strategic

M&A or partnership speculation (scarcity value of allogeneic assets)

medium-term Impact: Medium Direction: Bullish

Historical M&A in cell therapy: Bristol/Juno ($9B, 2018), Gilead/Kite ($12B, 2017), Novartis/AveXis ($8.7B, 2018). Allogeneic scarcity + Dagger tech + $674M market cap = potential strategic target if trial trajectory positive.

{ "verdict_label": {"it": "Giudizio: Moderatamente Attraente", "en": "Verdict: Moderately Attractive"}, "verdict_text": {"it": "Allogene è biotech clinico-stage con piattaforma CAR-T allogenico. Cema-cel in Phase 2 pivotale (ALPHA3) per LBCL prima linea: dati interim MRD positivi ad aprile 2026. FV base $2.75 = +41% vs prezzo $1.95, ma downside al floor cassa −72%. ALLO-329 in autoimmune (3 FDA Fast Track) apre secondo grande TAM. Speculativo — event risk binario per primary EFS mid-2028.", "en": "Allogene is clinical-stage biotech with allogeneic CAR-T platform. Cema-cel in pivotal Phase 2 (ALPHA3) for 1L LBCL: positive MRD interim data April 2026. Base FV $2.75 = +41% vs $1.95 price, but downside to cash floor −72%. ALLO-329 autoimmune (3 FDA Fast Tracks) opens second large TAM. Speculative — binary event risk on primary EFS mid-2028."}, "bull_points": [ {"it": "ALPHA3 MRD interim aprile 2026: 58.3% vs 16.7% osservazione", "en": "ALPHA3 MRD interim April 2026: 58.3% vs 16.7% observation"}, {"it": "ALLO-329 autoimmune: 3 FDA Fast Tracks su lupus/myositis/scleroderma", "en": "ALLO-329 autoimmune: 3 FDA Fast Tracks on lupus/myositis/scleroderma"}, {"it": "Cash runway a Q1 2029 dopo aumento capitale $200M aprile 2026", "en": "Cash runway to Q1 2029 after $200M April 2026 capital raise"} ], "bear_points": [ {"it": "Pre-revenue con burn $165M/anno: aumento capitale quasi certo 2027-2028", "en": "Pre-revenue with $165M/yr burn: capital raise near-certain 2027-2028"}, {"it": "Diluzione +9.93% YoY, proxy per raddoppiare share authorization", "en": "Dilution +9.93% YoY, proxy to double share authorization"}, {"it": "Primary EFS solo mid-2028: 2 anni di event risk binario", "en": "Primary EFS only mid-2028: 2 years of binary event risk"} ], "risks": [ {"it": "ALPHA3 primary EFS binario: miss = ritest del floor cassa $0.85-1", "en": "ALPHA3 primary EFS binary: miss = retest of cash floor $0.85-1"}, {"it": "Short interest 18.36% del outstanding (23.42% del float): amplifica volatilità", "en": "Short interest 18.36% of outstanding (23.42% of float): amplifies volatility"}, {"it": "Concorrenza CAR-T autologhi già approvati (Yescarta, Breyanzi) in 1L", "en": "Approved autologous CAR-T competition (Yescarta, Breyanzi) entering 1L space"} ] }

Sources & Disclaimer

Sources: StockAnalysis.com (real-time price + statistics + history), SEC EDGAR (10-Q Q1 2026 allo-20260331, 8-K earnings releases, PRE 14A proxy), Allogene investor relations (Q1 2026 earnings press release 2026-05-13, ALLO-329 IND clearance, ALPHA3 interim results April 2026), GlobeNewswire (ALLO-316 JCO publication 2026-07-15, CEO succession 2026-05-28, ALLO-329 preclinical data Nature Communications 2026-04-15), OncLive (cema-cel MRD clearance analysis), Reuters (Allogene ends China cell therapy deal with Overland 2026-05-13), Seeking Alpha (cash runway to Q1 2029 analysis), Investing.com (real-time quote), CNN Markets. Market data — last verified close 2026-07-21: ALLO $1.95, market cap ~$674M, 52W: $0.98–$4.46, 345.15M shares outstanding. Short interest: 18.36% of shares outstanding (23.42% of float, DTC 6.35). Cash Q1 2026: $266.9M, net cash $185.8M. Analyst consensus PT $8.49 (Buy, 13 analysts, updated Jul 2026). Beta 0.46. Q2 2026 earnings scheduled 2026-08-12 after market close. New CEO Zachary Roberts effective 2026-07-01. This document is for informational purposes only and does not constitute financial or investment advice.